Retatrutide · For Type 2 diabetes

Retatrutide for Type 2 diabetes

A1C control with the next-gen GLP-1. Retatrutide for diabetes?

S-Tier (pending) Weight Loss RCT (late-stage)

New to peptides? Start with the foundations ->

Why people use Retatrutide for Type 2 diabetes

A1C control with the next-gen GLP-1. Retatrutide for diabetes? The short answer: yes, this is one of the more-discussed uses for Retatrutide - but the evidence quality and the right protocol depend on what you're actually trying to fix.

This page covers what's known, what's not, and what the editorial take is for normal humans considering Retatrutide for Type 2 diabetes.

What the evidence says

Evidence tier: RCT (late-stage). Late-stage human trials are reporting; FDA review pending. Real evidence, near-final.

Phase-2 trial showed A1C drops of up to 2.0 percentage points at 36 weeks.
Comparable or slightly better A1C control than Tirzepatide head-to-head.
FDA path includes Type 2 diabetes indication; timing depends on Phase 3.

Protocol notes

Same titration as for weight loss. Endocrinology coordination.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

How it's dosed (quick version)

You start at 2mg once a week and step up every 4 weeks. Trial doses ran 1mg up to 12mg weekly. One shot, under the skin, same day each week. The drug is not yet FDA-approved - most US users get compounded versions through telehealth. Always with a doctor.

Typical starting dose: 2 mg subQ (under-the-skin shot) once weekly for the first 4 weeks. Some prescribers start at 1 mg if the patient is sensitive to GLP-1 side effects.
Typical maintenance dose: Most users in TRIUMPH-1 settled between 4 mg and 12 mg weekly. The 8 mg and 12 mg arms produced the most weight loss.
Frequency: Once weekly. Same day each week.
Cycle length: Indefinite for chronic obesity or diabetes (assuming approval). Some users do 6 to 12 months for a defined goal.

Full dosing breakdown ->

What to skip

Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

Full Retatrutide directory entry - status, sourcing, studies, what to skip
What are peptides - if you skipped the foundation
How peptides actually work - mechanism in plain English
The Tier List - which ones to take seriously
Subscribe to the dispatch

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free

Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine